Reserch on the effect of losartan on diastolic heart failure patients with hyperuricemia

Reserch on the effect of losartan on diastolic heart failure patients with hyperuricemia - Losartan study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007846

Enrollment

Registered

2012-05-01

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elderly diastolic heart failure patients with hyperuricemia

Interventions

Losartan(12 week) ACE-inhibitor(12 week)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 65 years old or over Hypertension Undertreatment of ACE inhibitor Serum uric acid level 7.0mg/dl or over

Exclusion criteria

Exclusion criteria: Medication for high uric acid Creatinine level 2.0mg/dl or over Serum potassium level 5.0meq/l or over Clinical history of Gouty attack Undertreatment of angiotensin receptor blocker NYHA4

Design outcomes

Primary

Measure	Time frame
Change of uric acid level	—

Secondary

Measure	Time frame
1.NYHA 2.Rho-kinase activity of circulating leukocyte 3.cyclophilin A, 8-isoproatane 4.pentraxin3, Hs-CRP 5.NT-proBNP 6.renin activity, aldsterone activity 7.echocardiography: ejection fraction, diastolic function(E/A,E/e') 8.flow mediated dilation 9.urinary albumin-to-creatinine ratio 10.Hospitalization for worsenig heart failure,all cause death	—

Countries

Japan

Contacts

Public ContactTsuyoshi Takada

Tohoku University Graduate School of Medicine Department of Cardiovascular Medicine

takada006@cardio.med.tohoku.ac.jp022-717-7153

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026